Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Century Therapeutics (IPSC) Operating Income (2022 - 2025)

Historic Operating Income for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to -$36.1 million.

  • Century Therapeutics' Operating Income fell 383.74% to -$36.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$33.9 million, marking a year-over-year increase of 7656.12%. This contributed to the annual value of -$138.1 million for FY2024, which is 573.81% up from last year.
  • Per Century Therapeutics' latest filing, its Operating Income stood at -$36.1 million for Q3 2025, which was down 383.74% from -$34.7 million recorded in Q2 2025.
  • Over the past 5 years, Century Therapeutics' Operating Income peaked at $74.2 million during Q1 2025, and registered a low of -$43.8 million during Q4 2023.
  • Its 4-year average for Operating Income is -$27.7 million, with a median of -$34.8 million in 2024.
  • As far as peak fluctuations go, Century Therapeutics' Operating Income plummeted by 3139.37% in 2023, and later skyrocketed by 33691.59% in 2025.
  • Century Therapeutics' Operating Income (Quarter) stood at -$33.3 million in 2022, then crashed by 31.39% to -$43.8 million in 2023, then grew by 14.8% to -$37.3 million in 2024, then increased by 3.11% to -$36.1 million in 2025.
  • Its last three reported values are -$36.1 million in Q3 2025, -$34.7 million for Q2 2025, and $74.2 million during Q1 2025.